Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia
Highly effective treatments for chronic lymphocytic leukemia (CLL) have the potential to reduce significant tumor burden to single cells and therefore require sensitive tools to assess for minimal residual disease (MRD) in bone marrow (BM) biopsies. Flow cytometry (FC) is the current gold standard for detection of MRD, but requires a specialized facility, specific antibody panels, collecting hundreds of thousands-to-millions of cells, and personnel with expertise in the analysis and interpretation of FC MRD data, which may not be feasible in many small laboratories. Dual-antibody immunohistochemistry (DA-IHC) can identify abnormal populations better than morphology alone, but its correlation with FC assessment is not known. Our aims are to characterize the efficacy of DA-IHC in assessing BM samples post-treatment and to compare results with FC to evaluate for residual disease in CLL. We collected 2-year post-therapy data from 33 CLL patients on two treatment protocols, chemoimmunotherapy (CIT) and single agent ibrutinib (IB), as well as BMs from 10 healthy volunteers as morphologic controls. BM biopsy specimens were examined for the presence or absence of CLL based on morphologic evidence of lymphoid infiltration and aberrant co-expression of CD5 and PAX5 DA-IHC. FC using a standard CLL antibody panel was performed in parallel. All IB patients had residual disease detected by DA-IHC and FC, although five patients (22%) were morphologically negative by routine hematoxylin and eosin (H&E) stain. Those without overt morphologic evidence of disease showed DA-IHC-positive interstitial single cells and were positive for residual disease by FC. The assessments by DA-IHC and FC were significantly correlated (p = 0.004). Four patients (40%) treated with CIT were morphologically negative by H&E, and two of these had no detectable CLL by either DA-IHC or FC. The other two patients had low-level disease detected by both DA-IHC and FC. The MRD levels identified by DA-IHC were correlated with those by FC (p < 0.0001). We characterized the efficacy of DA-IHC in assessing CLL post-treatment and found assessments by DA-IHC and FC were statistically significant in both the IB- and CIT-treated patients. These findings suggest DA-IHC could accurately detect residual disease in cases lacking morphologic evidence by H&E alone. DA-IHC may be a useful tool in current practice as another sensitive and efficient method to assess for MRD in CLL.
KeywordsDual-antibody immunohistochemistry Chronic lymphocytic leukemia Minimal residual disease
Compliance with ethical standards
Conflict of interest
Pharmacyclics and Novartis provided study drug and research support for the study. M.F. is employed at Merck & Co., Inc., Kenilworth, NJ, USA; owns stocks; and has received travel support from Merck. M.F. was an employee of the National Institutes of Health, Bethesda, MD, at the time of this study. A.W. received research support from Pharmacyclics, LLC, an AbbVie Company. Other authors declare that they have no conflict of interest.
- 2.Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 111(12):5446–5456CrossRefGoogle Scholar
- 3.Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 98(1):29–35CrossRefGoogle Scholar
- 9.Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol : Off J Am Soc Clin Oncol 30(9):980–988CrossRefGoogle Scholar
- 10.Santacruz R, Villamor N, Aymerich M, Martinez-Trillos A, Lopez C, Navarro A, Rozman M, Bea S, Royo C, Cazorla M, Colomer D, Gine E, Pinyol M, Puente XS, Lopez-Otin C, Campo E, Lopez-Guillermo A, Delgado J (2014) The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica. 99(5):873–880CrossRefGoogle Scholar
- 12.Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 376(9747):1164–1174CrossRefGoogle Scholar
- 13.Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M, international group of investigators, German CLL Study Group (GCLLSG) (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942CrossRefGoogle Scholar
- 15.Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110CrossRefGoogle Scholar